Christin Melton | Authors


Novartis Buys Into Gene Editing With CRISPR/Cas9

January 12, 2015

The start of 2015 brought news from Novartis that it had signed an agreement with Intellia Therapeutics and Caribou Biosciences to license its proprietary CRISPR/Cas9 gene editing platform to develop novel treatments for chronic genetic-based diseases.